Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25446265 | 1.00 | MEN1 (0.44) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL24510299 | 1.00 | MEN1 (0.44) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL21096853 | 0.99 | MEN1 (0.44) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL25855807 | 0.93 | MEN1 (0.41) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL14007040 | 0.92 | KMT2A (0.51) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL27214060 | 0.91 | KMT2A (0.54) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL31749265 | 0.91 | KMT2A (0.54) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL20586242 | 0.85 | KMT2A (0.48) | MEN1KMT2AADAMTS5POLBTP53 | |
| SCHEMBL12972568 | 0.84 | MEN1 (0.45) | MEN1KMT2AADAMTS5POLBALDH1A1 | |
| SCHEMBL14123991 | 0.84 | NPC1 (0.44) | MEN1KMT2AADAMTS5TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | MEN1 3872/4885KMT2A 2073/4885ADAMTS5 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.